Vertex Pharmaceuticals Inc VRTX:NASDAQ

Last Price$183.38Cboe Real-Time Last Sale as of 1:32PM ET 6/20/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+1.63(0.90%)
Bid (Size)$183.24 (32)
Ask (Size)$183.43 (100)
Day Low / High$181.27 - 186.33
Volume553.9 K
 

View Biotechnology IndustryPeer Comparison as of 06/20/2019

 

Vertex Pharmaceuticals Inc ( NASDAQ )

Price: $183.38
Change: +1.63 (0.90%)
Volume: 553.9 K
1:32PM ET 6/20/2019
 
 

Biogen Inc ( NASDAQ )

Price: $235.20
Change: +1.31 (0.56%)
Volume: 972.9 K
1:33PM ET 6/20/2019
 
 

Illumina Inc ( NASDAQ )

Price: $357.64
Change: +5.70 (1.62%)
Volume: 532.0 K
1:32PM ET 6/20/2019
 
 

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $321.27
Change: +10.44 (3.36%)
Volume: 960.3 K
1:32PM ET 6/20/2019
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 

Read more news Recent News

Sector Update: Biotechs Lift Health Care Stocks to Large Gain
3:55PM ET 6/07/2019 MT Newswires

Top Health Care Stocks JNJ +1.70% PFE +0.80% ABT +1.07% MRK +1.38% AMGN +0.67% Health care stocks were ending near their session highs, with the NYSE...

Sector Update: Health Care Stocks Climbing More Than 1% as a Group
1:59PM ET 6/07/2019 MT Newswires

Top Health Care Stocks JNJ +1.71% PFE +0.82% ABT +0.77% MRK +1.35% AMGN +0.32% Health care stocks were posting large gains, including a 1.3% advance...

Vertex Pharmaceuticals Expands Collaboration with CRISPR, Buys Exonics Therapeutics
11:00PM ET 6/06/2019 MT Newswires

Vertex Pharmaceuticals (VRTX) said it expanded its collaboration with CRISPR Therapeutics (CRSP) and acquired Exonics Therapeutics to enhance its gene...

Vertex Pharma to Seek Approvals for Triple Combination of VX-445, Tezacaftor and Ivacaftor in Cystic Fibrosis - Stock Up 2%
1:29PM ET 5/30/2019 MT Newswires

Vertex Pharmaceuticals (VRTX) said on Thursday it has selected the triple combination of the next-generation corrector VX-445, tezacaftor and ivacaftor to...

View all Commentary and Analysis

The Zacks Analyst Blog Highlights: Deere, Las Vegas Sands, Vertex, Tesla and Keurig Dr Pepper
8:38AM ET 6/20/2019 Zacks

The Zacks Analyst Blog Highlights: Deere, Las Vegas Sands, Vertex, Tesla and Keurig Dr Pepper

Top Stock Reports for Deere, Las Vegas Sands & Vertex
1:02PM ET 6/19/2019 Zacks

Top Stock Reports for Deere, Las Vegas Sands & Vertex

Vertex Makes Strong Push Into Crispr Tech With 2 Deals At Once
4:31PM ET 6/17/2019 Seeking Alpha

BIIB Is For Buy-O-Gen
10:30AM ET 6/12/2019 Seeking Alpha

Company Profile

Business DescriptionVertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA. View company web site for more details
Address50 Northern Avenue
Boston, Massachusetts 02210
Phone+1.617.341.6100
Number of Employees2,500
Recent SEC Filing06/07/20198-K
Chairman, President & Chief Executive OfficerJeffrey M. Leiden
Chief Financial Officer & Executive Vice PresidentCharles F. Wagner
Chief Scientific Officer & EVP-Global ResearchDavid Matthew Altshuler
Chief Medical Officer & Executive Vice PresidentReshma Kewalramani

Company Highlights

Price Open$183.52
Previous Close$181.75
52 Week Range$145.37 - 195.81
Market Capitalization$47.0 B
Shares Outstanding256.1 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement07/24/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings21.90
Earnings per Share$8.37
Beta vs. S&P 500N/A
Revenue$3.0 B
Net Profit Margin66.24%
Return on Equity58.43%

Analyst Ratings as of 06/07/2019

Buy
19
Overweight
1
Hold
6
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset